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Background:  FP-01.1  is a  novel  synthetic  inﬂuenza  A vaccine  consisting  of  six ﬂuorocarbon-modiﬁed  35-
mer  peptides  that  encapsulate  multiple  CD4+  and CD8+ T-cell  epitopes  and  is  designed  to  induce  an
immune  response  across  a broad  population.
Methods:  FP-01.1  was  evaluated  for  safety  and  immunogenicity  in  a  randomised,  double-blind,  placebo-
controlled,  dose-escalation,  phase  I clinical  study  in  healthy  adult  volunteers  (n = 49).  IFN  ELISpot  assays
and multicolour  ﬂow  cytometry  were  used  to  characterise  the  immune  response.
Results: FP-01.1  was  safe  and  well  tolerated  at  all  doses  tested  with  a similar  adverse  event  pro-
ﬁle  in actively  vaccinated  subjects  compared  with controls.  Maximum  immunogenicity  was  in the
150  g/peptide  dose  group  where  a robust  response  (243  spots/million  PBMC)  was  demonstrated  in
75%  subjects  compared  with  0%  in  placebo  controls.  All  six  peptides  were  immunogenic.  FP-01.1  induced
dual  CD4+  and CD8+  T cell  responses  and  vaccine-speciﬁc  T cells  cross-recognise  divergent  inﬂuenzaafety
luoropeptides
strains.
Conclusions:  This  ﬁrst-in-human  study  showed  that  FP-01.1  has  an  acceptable  safety  and  tolerability
proﬁle  and  generated  robust  anti-viral  T cell  responses  in a high  proportion  of subjects  tested.  The
results  support  the  further  clinical  testing  of  FP-01.1  prior  to  clinical,  proof-of-concept,  live viral  challenge
studies.
ublis© 2014  The  Authors.  P
. Introduction
Inﬂuenza epidemics are associated with signiﬁcant morbidity
nd mortality, particularly in at-risk groups such as the elderly [1].
nﬂuenza A can be subjected to major antigenic shift in one or both
urface antigens presenting a major risk of worldwide pandemic
ith a signiﬁcant impact on human health and the economy [2,3].
Current inactivated trivalent inﬂuenza vaccine (TIV) strategies
ely on the induction of an antibody-mediated immune response
peciﬁc for the antigenically varying hemagglutinin (HA) surface
ntigen. TIV have only moderate efﬁcacy or effectiveness [4–5] and
s particularly impeded when the circulating strain has drifted sig-
iﬁcantly from the vaccine strain. A recent meta-analysis of TIV
tudies found that anti-HA antibodies are only partial correlates of
 Clinical trials registration. NCT01265914.
∗ Corresponding author at: Immune Targeting Systems, 2 Royal College Street,
ondon, NW1  0NH, UK. Tel.: +44 (0) 2076914908; fax: +44 (0) 2076819129.
E-mail address: campbell.bunce@its-innovation.com (C.J. Bunce).
1 Equal contribution as non-clinical principal investigators.
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.006
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
protection in the general population and poor correlates of protec-
tion in the elderly [4].
There is a growing body of evidence supporting the pro-
tective contribution of cell-mediated immune (CMI) responses
to inﬂuenza, in the absence of a speciﬁc antibody response,
which are poorly induced by TIVs [6–8]. Cytotoxic T lympho-
cyte activity was associated with reduced virus shedding in a
cohort of experimentally infected volunteers with no detectable
antibody responses against the experimental strain [9]. Clini-
cal studies demonstrated that T cell responses, as measured
by the antiviral mediator granzyme B, were directly correlated
with protection against inﬂuenza in the elderly [10,11]. Two
recent studies have established a direct correlation between pre-
existing T cell responses and reduced severity of inﬂuenza disease
[12,13].
A major advantage of cell-mediated over humoral immunity
is that T cells can recognise epitopes thoughout the virus pro-
teome, including from internal antigens which are conserved
across a range of inﬂuenza subtypes, and thus provide broad
cross-protective immunity to both seasonal strains and pandemics
[14,15].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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We  have developed a novel inﬂuenza vaccine strategy based
n linking a ﬂuorocarbon moiety to 35-mer peptides speciﬁc for
onserved, internal inﬂuenza antigens. This vaccine, called FP-01.1
FlunisynTM), is a chemically synthesized, freeze-dried preparation
f six different synthetic peptides conjugated to an inert ﬂuoro-
arbon chain. Linking a ﬂuorocarbon chain to peptides promotes
heir half-life in vivo, thereby putatively allowing more prolonged
xposure of the peptides to the immune system and enhancing
mmunogenicity.
We report the results of a ﬁrst-in-human phase I clinical study
n healthy adult volunteers assessing the safety, tolerability and
mmunogenicity of a novel, pan-inﬂuenza A ﬂuorocarbon-modiﬁed
eptide vaccine designed to induce or amplify pre-existing and
ross-protective T cell responses.
. Materials and methods
.1. Vaccine design
Vaccine FP-01.1 comprises six different synthetic 35-mer
eptides, each conjugated to the ﬂuorocarbon moiety C8F17(CH2)2-
OOH and are derived from inﬂuenza A internal proteins;
ucleoprotein, matrix protein and polymerase basic 1 and poly-
erase basic 2 proteins:
P44, HMAIIKKYTSGRQEKNPSLRMKWMMAMKYPITADK;
P220, VAYMLERELVRKTRFLPVAGGTSSVYIEVLHLTQG;
P1100a, YITRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE;
P1116b, APIMFSNKMARLGKGYMFESKRMKLRTQIPAEMLA;
P3071, DQVRESRNPGNAEIEDLIFLARSALILRGSVAHKS;
P3845, DLEALMEWLKTRPILSPLTKGILGFVFTLTVPSER.
Each peptide sequence was selected on the basis of a high level
f conservation across H1–H9 inﬂuenza A strains isolated from
umans, birds and pigs. For example, there is 99.0% and 97.1%
dentity between selected peptides and corresponding sequences
rom avian H5N1 and swine H1N1 (2009) respectively. The bioin-
ormatics process also selected sequences that contain predicted
LA binding motifs across the most globally prevalent HLA class
I molecules (n = 13) and HLA class I molecules (n = 35) in order to
chieve a high population coverage. In addition, peptide selection
voided anticipated large-scale manufacturing constraints.
Each peptide was manufactured under current Good Man-
facturing Practice (cGMP) conditions using solid phase Fmoc
hemistry. FP-01.1 (considered as the Investigational Manufac-
ured Product, IMP) was produced in accordance with cGMP
y Carbogen Amcis, France and manufactured as a freeze-dried
roduct containing 350 g of each peptide and 31.5 mg  manni-
ol. IMP  was reconstituted in cGMP 28 mM l-histidine buffer, to
reate a homogeneous solution at a concentration of 500 g/mL
er peptide with close to neutral pH and an osmolality of
00 mOsm/L.
.2. Subjects and study design
A randomised, double-blind, placebo-controlled, ascending
ose study to assess the safety, tolerability and immunogenicity of
epeated intramuscular administration of FP-01.1 in healthy vol-
nteers was performed at Hammersmith Medicines Research Ltd.,
ondon (Fig. 1). The study was conducted in accordance with EU
irective 2001/20/ECand ICH GCP. The protocol was  approved by
he Medicines and Healthcare Products Regulatory Agency in the
K and the National Research Ethics Service Committee London
Brent). Written informed consent was obtained from 49 healthy
ale and female subjects aged between 22 and 55 years that 33 (2015) 396–402 397
were enrolled (Table 1). Detailed inclusion/exclusion criteria are
described in clinicaltrials.gov under identiﬁer NCT01265914. The
primary safety endpoints were tolerability, incidence of treatment
emergent adverse events (TEAEs), clinically signiﬁcant changes
in laboratory safety tests, 12-lead electrocardiograms, vital signs
and physical examination ﬁndings. Subjects were provided with
diary cards to report AEs when not at the clinical site. Randomisa-
tion codes were computer-generated by an unblinded statistician
and subjects were sequential assigned an unused randomisation
number. With the exception of the pharmacist and statistician,
all staff, subjects and employees of ITS remained blinded until
the formal unblinding of the study. Three ascending dose cohorts
(50, 150 and 500 g/peptide) of 16 subjects (12 active:4 placebo)
administered test vaccine on Day 1, 29 (main study phase) and 99
(follow up phase). Each cohort started with a sentinel group of four
subjects and safety data was  reviewed before progression to the
remaining subjects. Placebo subjects received 45 mg/mL  mannitol
in l-histidine buffer. Adverse events were recorded and presented
from day 7 to day 113. No formal sample size calculations were per-
formed. The study was conducted between August 2010 and March
2011 (up to day 113).
2.3. Peptides for in vitro testing
35-mer peptides, at ≥95% purity, corresponding to the antigens
in FP-01.1 (but without the ﬂuorocarbon chain) were used as in
vitro recall antigens in ELISpot assays. A mixture of the six peptides
(LPMIX6) and a mixture of 90 putative CTL (cytotoxic T lymphocyte)
target peptides (SPMIX; 9-mer peptides predicted using SYFPEITHI
(www.syfpeithi.de)) derived from the 35-mer peptide sequences
were used as antigens for ﬂow cytometric analysis and for multiplex
cytokine assays.
2.4. PBMC isolation and cryopreservation
Within 8 h of collection, PBMC were separated from heparinised
blood by density gradient centrifugation on Histopaque-1077
(Sigma). PBMC were cryopreserved at 1 × 107 cells/mL in 10%
dimethyl sulfoxide/foetal calf serum and stored in liquid nitrogen.
Samples were transferred between sites using a liquid nitrogen
dry shipper. Only cell samples with >80% viability (as assessed
by propidium iodide staining and ﬂow cytometry) were ana-
lysed. Median cell viability and recovery were 96% and 79%
respectively.
2.5. ELISpot assay
An IFN enzyme-linked immunosorbent spot (ELISpot) assay
was utilised to measure the primary immunogenicity endpoint
from samples collected up to day 43 and was conducted by Immune
Health (Belgium) following Good Clinical Laboratory Practice
guidelines. Samples from each individual subject were tested in
parallel on the same day to minimise assay variability. PVDF
plates (Millipore) were coated overnight at 4 ◦C with anti-human
IFN antibody (R&D systems) and blocked for >1 h (1% BSA (PAA),
5% sucrose (Fisher), Dublecco’s-PBS (Invitrogen)). Plates were
washed with complete media (5% human serum (Sigma), RPMI
Glutamax (Invitrogen) and gentamicin (Invitrogen)) prior to use.
2 × 105 PBMC were stimulated with individual 35-mer peptides
(10 g/peptide/mL). Negative (complete medium) and positive
(phytohaemagglutinin and CEF (peptides from cytomegalovirus,
EBV, and inﬂuenza)) controls were included. After 18 h of culture,
plates were washed and incubated with biotinylated anti-human
IFN (R&D systems) followed by streptavidin-HRP. Production
of IFN was detected using the ELISpot blue colour module
(R&D Systems) as per manufacturer’s instructions. Plates were
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Exc lud ed (n= 19) 
Not mee ting  inclusion  criteria (n= 12 )  
Declined  to pa rticipa te (n= 6 )  
Other reasons (n= 1)  
Ass essed f or eligibil ity (n= 68 ) 
Placeb o 
(n = 12 ) 
Rando mised  (n= 49) 
FP-01.1 
150 µg/pe ptide 
(n = 12 )  
FP-01 .1 
50 µg/pep tide 
(n = 12 )  
FP-01 .1 
500 µg/pe ptide 
(n = 13 )  
Lost to follow (n=0) 
Discon tinued  interven tion  
(n=0) 
Lost to follow up  (n=0) 
Discon tinued  interven tion  
(n=0) 
Lost to follow up  (n=0) 
Discon tinued  interven tion  
(n=0) 
Lost to follow up  (n=0) 
Discon tinued  interven tion  
due to protocol violation  
(n=1) 
Ana lys ed for 
immun ogen icity (n=12 ) 
Ana lys ed for safety (n=12) 
Ana lys ed for 
immun ogen icity (n=12 ) 
Ana lys ed for safety (n=12) 
Ana lys ed for 
immun ogen icity (n=12 ) 
Ana lys ed for safety (n=12) 
Ana lys ed for 
immun ogen icity (n=12 ) 
Ana lys ed for safety (n=13) 
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canned and counted using an automated ELISpot reader sys-
em (AID). Results are expressed as Spot Forming Cells (SFC)/106
BMC.
.6. Flow cytometric analysis using intracellular cytokine staining
PBMC were stimulated with either complete medium alone
negative control) or a mixture of LPMIX6 (5 g/mL/peptide) and
PMIX6 (ﬁnal concentration of 5 g/mL) for 20 h, or a mixture
f Phorbol 12-Myristate 13-Acetate (10 ng/mL) and ionomycin
1 g/mL) for 3 h was used as a positive control. Golgiplug (BD)
as added for the ﬁnal 3 h of cell culture. Cells were stained with
he following antibodies from BD Biosciences: CD3-APC-H7 (clone
K7), CD4-APC (clone SK3), CD8-PE-Cy7 (clone SK1) and IFN-PE
clone B27). Samples and appropriate controls were collected on
 BD FACSCanto II and analysed using FACSDiva v6.1.2. FP-01.1-
peciﬁc cytokine production was recorded as expression above
ackground.
.7. Cytokine and granzyme B measurements in culture
upernatants
2 × 105 PBMC were incubated with complete media (nega-
ive control) or LPMIX6 at 5 g/peptide/mL for 48 h at 37 ◦C,
able 1
emographic characteristics of study participants.
Placebo (n = 12) FP-01.1 50 g/peptide
(n = 12)
Gender (n) Male/Female 10/2 10/2 
Ethnicity (n) Europid 7 9 
Afro-Caribbean 3 0 
Asian/Indian 2 3 
Age  (y) Median [range] 27 [22–54] 36 [25–55] 
BMI  (kg/m2) Median [range] 25 [20–31] 26 [22–32]  diagram.
5% CO2. Supernatants were frozen at −20 ◦C until analysis using
a cytometric bead array (BD Biosciences) as per manufacturer’s
instructions.
2.8. Cross-reactivity assay
Inﬂuenza A/California/7/2009, A/Hong Kong/8/68 and A/Puerto
Rico/8/34 were from Advanced Biotechnologies Inc., while A/
Brisbane/59/2007, A/Panama/2007/99 and A/Wisconsin/67/2005
were a kind gift from Retroscreen Virology Ltd. A549 cells (ATCC;
HLA-A2 restricted) were seeded at 1.5 × 104 cells/well and viruses
were added at 3–10 MOI. After overnight culture, A549 cells were
washed and were co-cultured with 2.25 × 105 PBMC/well at a ratio
of 1:15 for 24 h. PBMC were selected from HLA-A2+ vaccine respon-
ders (n = 3). Negative controls of PBMC alone and PBMC/A549 cells
without virus were assessed in parallel. Cell culture supernatants
were collected and frozen at −20 ◦C before analysis of IFN and
Granzyme B by cytometric bead array.
2.9. Statistical analysisIn the primary immunological analysis, an ELISpot result was
considered positive if the number of SFC was greater than 25
SFC/106 PBMC and greater or equal to the average negative
FP-01.1 150 g/peptide
(n = 12)
FP-01.1 500 g/peptide
(n = 13)
All subjects (n = 49)
12/0 11/2 43/6
8 9 33
0 2 5
4 2 11
36 [26–50] 39 [22–52] 36 [22–55]
26 [22–31] 25 [22–32] 25 [20–32]
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ontrol plus two standard deviations of the negative control. The
alue of the negative control was subtracted from all ELISpot data.
accine responder thresholds were set after the study was  com-
leted using ELISpot data from the placebo group (n = 12) so that no
ubjects in the placebo group were deﬁned as vaccine responders.
 responder was deﬁned as a subject with a FP-01.1-speciﬁc pos-
tive ELISpot response above a threshold of >125% of the baseline
esponse and an ELISpot score greater than the baseline response
lus 63 SFC to the sum of individual peptide responses measured at
 minimum of one time point after vaccination. For analysis of the
readth of response, a threshold of >125% of the baseline response
nd greater than the baseline response plus 25 SFC to individual
eptide responses was applied.
. Results
.1. Vaccine tolerability and safety
FP-01.1 demonstrated an acceptable safety proﬁle at all dose
evels tested (Table 2). Across the duration of the study (127
ays) a total of 46 subjects reported 186 TEAEs. The most com-
on  adverse events were respiratory disorders and headache: 32
ubjects (65.3%) had respiratory disorders (oropharyngeal pain,
hinorrhoea, cough, nasal congestion, and sneezing); and 24 sub-
ects (49.0%) reported headache. Headache was more common after
ctive treatment than after placebo, but the incidence of respiratory
isorders was similar in all treatment groups. The relatively high
ncidence of these symptoms may  be attributed to the daily moni-
oring of symptoms for 127 days and that the study was  conducted
uring the UK winter. Most of these TEAEs were mild in severity
nd classed by the investigator as unlikely to be related to immun-
sation with FP-01.1. Only 12 events were considered related to
P-01.1 treatment and those events were predominantly injection
ite reactions. Two severe adverse events were reported (Table 2)
nd were unrelated vaccine administration.
None of the laboratory values showed changes that were clini-
ally signiﬁcant or could reasonably be attributed to administration
f FP-01.1. The results of all physical examinations were normal. All
ital signs and ECG recordings were considered to be within normal
imits, or, if outside the reference range, of no clinical signiﬁcance.
Injection site tolerability was favourable, four subjects had mild
ocal reactions and those occurred only after the ﬁrst injection of
P-01.1. No itching was reported. Redness was the most frequently
eported local reaction, observed only after active treatment, and
ost common at 24 h after the second injection. No subject had
 severe local reaction to the study medication. Overall, FP-01.1
as well tolerated up to and including the maximum dose of
00 g/peptide FP-01.1 administered on three occasions.
.2. Immunological analysis
The primary immunological analysis measured the frequency
f vaccine-speciﬁc T cells in PBMC collected up to study day 43
sing an IFN ELISpot assay (Fig. 2). At baseline the median fre-
uency of T cells speciﬁc for FP-01.1 ranged between 34 and 60
FC/106 PBMC. Subjects immunised with 150 g/peptide showed
he greatest increase in T cell frequencies and maximum responses
ere at 7 days after the second injection, with a median response
f 243 SFC/106 PBMC (median increase of 198 SFC/106 PBMC
bove baseline; P < 0.05). Responder frequencies were 0%, 50%,
5% and 83% for the placebo, 50, 150 and 500 g/peptide groups
espectively. Analysis of subjects deﬁned as responders showed a
edian breadth of response of four out of the six peptides included
n the vaccine. All FP-01.1 peptides were immunogenic in the
tudy population (Supplementary Fig. 1) and analysis of subject 33 (2015) 396–402 399
HLA-restriction showed no difference between vaccine responders
and non-responders (Supplementary Table 1).
3.3. Characterisation of the T cell response
The phenotype of vaccine-induced IFN production was
assessed in a subset of subjects deﬁned as vaccine respon-
ders. Analysis by ﬂow cytometry shows signiﬁcant increases
in CD3 + CD4 + IFN+ and CD3 + CD8 + IFN+ cells were observed
(Fig. 3) after vaccination with FP-01.1. Analysis of PBMC culture
supernatants after a 48 h incubation with FP-0.1.1 peptides showed
post-vaccination increases in IFN, IL-2 and Granzyme B suggesting
an anti-viral phenotype.
3.4. Cross-recognition of naturally processed and presented viral
epitopes by FP-01.1-speciﬁc T cells
PBMC from FP-01.1-vaccinated subjects were tested for their
ability to recognise and respond to inﬂuenza antigens. Target
cells were prepared by incubating different inﬂuenza viruses with
A549 cells, a HLA-A2-expressing human lung epithelial cell line
permissive to inﬂuenza infection and replication. The ability of
vaccine-speciﬁc T cells (from HLA-A2+ subjects) to cross-recognise
target cells infected by different viruses was established by com-
paring responses from PBMC samples obtained before and after
vaccination. PBMC isolated post-vaccination produced more IFN
and granzyme B in response to target cells infected with different
H1N1 and H3N2 inﬂuenza strains (Fig4).
4. Discussion
In this ﬁrst-in-human study of the ﬂuorocarbon-modiﬁed pep-
tide vaccine FP-01.1, we found that intramuscular administration
of two  doses could induce a robust immune response (Fig. 4).
Immunisation with FP-01.1 was well tolerated: there was no
dose-dependent incidence of TEAEs, laboratory abnormalities, or
injection site reactions. No subject exhibited any marked local
or systemic reaction to vaccination on either the ﬁrst, second or
third exposure in any of the dosing cohorts. Administration of
150 g/peptide induced the optimum immune response measured
using an IFN ELISpot assay speciﬁc for vaccine peptides. All six
peptides included in FP-01.1 were immunogenic and a median
breadth of response of four out six peptides was recorded. The
response induced by FP-01.1 was seen to be cross-reactive, recog-
nising antigens processed and presented by virus-infected cells.
FP-01.1 was  designed to induce new and enhance existing
anti-viral CMI  responses to conserved, internal inﬂuenza antigens.
Mobilising an arm of the immune response that targets conserved
regions of the virus proteome allows the development of a vac-
cine that induces a broad cross-reactive immune response [16]. We
show that FP-01.1-speciﬁc T cells have the potential to cross-react
with different strains of inﬂuenza A. T cells induced by FP-01.1 vac-
cination could recognise naturally processed and presented viral
epitopes from multiple subtypes of disparate inﬂuenza virus strains
H1N1 and H3N2. The cross-reactive potential for FP-01.1-speciﬁc
T cells supports the notion that the vaccine would confer broad
protection, possibly against all inﬂuenza A strains.
The magnitude of the FP-01.1-speciﬁc T cell response measured
using the IFN ELISpot assay was highest in the 150 g/peptide
group and maximum responses were measured 7 days after the
second injection. The number of T cells required to provide clinical
beneﬁt against inﬂuenza disease has yet to be established and it is
difﬁcult to compare results of different studies using divergent re-
stimulation antigens. One study, using inactivated inﬂuenza virus
as an antigen, suggested that a frequency of 100 virus-speciﬁc
T cells per million PBMC is associated with protection against
400 J.N. Francis et al. / Vaccine 33 (2015) 396–402
Table 2
Frequency (%) of treatment emergent adverse events and injection site reactions in ≥2 subjects.
Placebo (n = 12) FP-01.1
50 g/peptide (n = 12)
FP-01.1
150 g/peptide (n = 12)
FP-01.1 500 g/peptide
(n = 13)
Systemic reactions ALL Grade 3 ALL Grade 3 ALL Grade 3 ALL Grade 3
Nervous system disorders (e.g. headache) 25.0 0.0 66.7 0.0 75.0 0.0 53.8 0.0
Respiratory, thoracic and mediastinal disorders 75.0 0.0 75.0 0.0 50.0 0.0 61.5 0.0
General disorders and administration site conditions 16.7 0.0 8.3 0.0 33.3 0.0 38.5 0.0
Musculoskeletal and connective tissue disorders 33.3 0.0 16.7 0.0 33.3 0.0 23.1 0.0
Gastrointestinal symptoms 8.3 0.0 0.0 0.0 8.3 0.0 30.0 0.0
Infections and infestations 16.7 0.0 16.7 0.0 16.7 0.0 15.4 0.0
Eye  disorders 16.7 0.0 0.0 0.0 8.3 0.0 7.7 0.0
OTHER  33.3 8.3* 25.0 0.0 41.7 8.3ˆ 53.8 0.0
Injection site reactions ALL Grade 2 and above ALL Grade 2 and above ALL Grade 2 and above ALL Grade 2 and above
Bruising 16.7 0.0 0.0 0.0 8.3 0.0 0.0 0.0
Induration 8.3 0.0 23.1 0.0 0.0 0.0 16.7 0.0
Redness 0.0 0.0 61.5 8.3** 50.0 0.0 75.0 0.0
Pain  (VAS score) 16.7 0.0 25.0 0.0 83.3 0.0 68.2 0.0
Note: Grade description is 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The two  severe adverse events are also considered serious but were not reportable.
* Epididymo-orchitis.
ˆ Wrist fracture.
** Moderate.
Fig. 2. Magnitude and kinetics of vaccine-induced responses. PBMC from each treatment group (n = 12/group; all subjects tested) were stimulated with peptides for 18 h
in  an IFN ELISpot assay. A. The graph represents vaccine-speciﬁc IFN response at baseline (average response at day -7 and day 1) and the maximal response recorded
post-vaccination for each subject and from each treatment group. Results are shown as the sum of responses to the six peptides in the vaccine and the line represents
the  median response post vaccination. Wilcoxon matched-pairs tests were used for statistical comparisons. Median background responses were <10 SFC/106 PBMC and no
differences in background responses between randomisation groups or pre- and post-vaccination were observed. B. IFN responses measured at intervals through the study
are  shown from the placebo and 150 g/peptide groups only. Data is shown as median and interquartile ranges.
Fig. 3. Phenotype of FP-01.1-speciﬁc cells. PBMC samples (n = 11; responders only) were selected from subjects deﬁned as vaccine responders at either baseline (day -7
or  day 1; pre) or post-vaccination at a time point where maximal IFN responses were detected using the primary ELISpot assay. A. The frequencies CD3+CD4+IFN+ and
CD3+CD8+IFN+ are shown as mean plus standard error of the mean after background subtraction as measured by ﬂow cytometry. Also refer to supplementary Table S1.
B.  PBMC were cultured with FP-01.1-peptides for 48 h and cell culture supernatants were analysed for IL-2, IFN and Granzyme B using a cytometric bead array. Wilcoxon
matched-pairs tests were used for statistical comparisons.
J.N. Francis et al. / Vaccine 33 (2015) 396–402 401
Fig. 4. Virus-based cross reactivity. PBMC samples (n = 3) were selected from HLA-A2+subjects deﬁned as vaccine responders at either baseline (day -7 or day 1; pre) or
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cost-vaccination at a time point where maximal IFN responses were detected u
trains  of inﬂuenza virus. Control cultures contained uninfected A549 cells. IFN
esponse ± standard error of the mean. A paired Student’s t-test was  used for statis
nﬂuenza in young children [17]. An intervention study, testing
he safety and efﬁcacy of a MVA-NP + M1  vaccine against inﬂuenza
hallenge, showed a more robust IFN response to the inﬂuenza
ntigens NP and M1  before virus challenge [18]. In the present
tudy, we show that FP-01.1 induces a dual CD4+ and CD8+ IFN
 cell response as well as the production of the anti-viral soluble
ediators granzyme B and IL-2. The ability to induce granzyme
 has particular importance in relation to inducing a protective
mmune response in the elderly where it has been associated with
rotection to infection [10].
The novel ﬂuoropeptide vaccine platform has been designed to
ddress the ‘shortfalls’ in the ﬁeld of T cell vaccine development,
nd to offer the following advantages: (1) production of chemically-
eﬁned peptides that can be produced economically on a large
cale; (2) formulation as a freeze-dried product, ensuring long term
tability with potential for stock-piling; (3) an acceptable safety
roﬁle, and unlike other ‘universal’ inﬂuenza vaccines [19,20] con-
ains no extraneous adjuvant or risk of genetic integration or
ecombination, to facilitate approval by regulatory authorities; (4)
 vaccine technology that supports repeat administration without
voking anti-vector immunity (in contrast with viral vectors); (5)
he ability to promote dual CD4+ and CD8+ T cell responses, with
igh responder frequency irrespective of HLA polymorphism. Our
esults show that FP-01.1 fulﬁls all these requirements.
Owing to its high degree of conservation across inﬂuenza A
ubtypes, FP-01.1 does not need to be changed in response to
he rapid evolution of seasonal strains or the emergence of pan-
emic inﬂuenza, and consequently could be used as the ﬁrst line
f defence during outbreaks. In the context of seasonal inﬂuenza,
P-01.1 could be used in conjunction with TIVs or QIVs thereby
xtending immunity to inﬂuenza B viruses. This combination may
rovide a more protective response due to the mobilisation of a
road cross-reactive T cell response alongside a highly speciﬁc anti-
ody response, with the T cell response induced by FP-01.1 playing
 particularly important role in the elderly who remain more vul-
erable to inﬂuenza A infection despite vaccination with TIV.
This study demonstrates that a ﬂuorocarbon-modiﬁed peptide
accine, without the need for an exogenous adjuvant, can induce a
igniﬁcant immune response to conserved internal inﬂuenza anti-
ens. Further clinical trials are required to establish protection in
uman viral challenge studies.otential conﬂicts of interest
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